New drug combo shows promise for Hard-to-Treat HER2 cancers

NCT ID NCT05593094

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tests a new drug called ZN-A-1041, taken as a capsule, for people with advanced HER2-positive solid tumors (cancers that have spread). The drug is given alone or with other standard cancer medicines. The main goals are to check safety, find the best dose, and see if it helps shrink tumors. About 210 adults whose cancer has not responded to prior treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa

Tucson, Arizona, 85712, United States
Asst Papa Giovanni XXIII

Bergamo, Lombardy, 24127, Italy
Auckland City Hospital

Auckland, 1023, New Zealand
Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Centre Georges Francois Leclerc

Dijon, 21000, France
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Clatterbridge Cancer Centre

Liverpool, Merseyside, L69 3GL, United Kingdom
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University School of Medicine

Durham, North Carolina, 27710, United States
EDOG - Institut Claudius Regaud - PPDS

Toulouse, Haute-Garonne, 31059, France
Fondazione Policlinico Universitario A Gemelli-Rome

Magnago, Lombardy, 20020, Italy
Fundacion Instituto Valenciano de Oncologia (IVO)

Valencia, 46009, Spain
Geelong Hospital

Geelong, Victoria, 3220, Australia
Gustave Roussy

Villejuif, 94800, France
Hospital Beata Maria Ana

Madrid, 28007, Spain
Hospital Clinic de Barcelona

Barcelona, 08036, Spain
Hospital Clinico San Carlos

Madrid, 28040, Spain
Hospital Clinico Universitario de Santiago

Santiago de Compostela, LA Coruna, 15706, Spain
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Ramon y Cajal

A Gudiña, Orense, 32540, Spain
Hospital Universitario Virgen Macarena

Seville, 41009, Spain
Hospital Universitario Virgen del Rocio

Las Cabezas de San Juan, Sevilla, 41730, Spain
Hospital Universitario de Jaen

Jaén, 23007, Spain
Institut Paoli-Calmettes

Marseille, 13009, France
Institut de Cancerologie de l Ouest

Saint-Herblain, 44805, France
Instituto Oncologico Dr. Rosell-Hospital Universitari Dexeus-Grupo Quironsalud

Barcelona, 08028, Spain
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

Argentona, Barcelona, 08310, Spain
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l - PPDS

Parma, Emilia-Romagna, 43126, Italy
MD Anderson Cancer Center

Houston, Texas, 77030-4000, United States
Sunshine Hospital

St Albans, Victoria, 3021, Australia
TOI Clinical Research

Cerritos, California, 90703-2684, United States
The Christie

Manchester, Lancashire, M20 4BX, United Kingdom
UCSF Helen Diller Family CCC

San Francisco, California, 94158, United States
University of Michigan Hospital

Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS ADVANCED SOLID TUMORS HER2-POSITIVE BREAST CANCER